Interferon-gamma-1b - InterMune/Maxygen

Drug Profile

Interferon-gamma-1b - InterMune/Maxygen

Alternative Names: IFN-gamma-1b - InterMune/Maxygen; IFN-γ-1b - InterMune/Maxygen; Interferon gamma-1b - InterMune/Maxygen; Maxy 50; Maxy-Gamma; Maxy-γ

Latest Information Update: 25 May 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Maxygen
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Hepatitis C; Pulmonary fibrosis

Most Recent Events

  • 06 Jun 2006 This programme is still in active development
  • 27 Sep 2004 Preclinical trials in Hepatitis C in USA (unspecified route)
  • 03 Oct 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top